Discontinued Product(2S)-a-Methylglutamic acid (Cat. No. 0809) has been withdrawn from sale for commercial reasons.
Reported to show agonist activity at mGlu receptors; full spectrum of activity awaits characterisation.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Kemp et al (1996) Agonists of cyclic AMP-coupled metabotropic glutamate receptors in adult rat cortical slices. Eur.J.Pharmacol. 309 79 PMID: 8864697
View Related Products by Target
Keywords: (2S)-a-Methylglutamic acid, (2S)-a-Methylglutamic acid supplier, Non-selective, mGlu, 0809, Tocris Bioscience
Citations for (2S)-a-Methylglutamic acid
Citations are publications that use Tocris products.
Currently there are no citations for (2S)-a-Methylglutamic acid.
Reviews for (2S)-a-Methylglutamic acid
There are currently no reviews for this product. Be the first to review (2S)-a-Methylglutamic acid and earn rewards!
Have you used (2S)-a-Methylglutamic acid?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.